La estrecha ventana del TRISCEND II: un paso adelante, ¿pero qué tan lejos?
Cirugía Cardiaca en México · 2025
DOI: 10.35366/118937 ↗At a glance
Journal article in Cirugía Cardiaca en México, 2025. Written by Ovidio A García-Villarreal and 2 co-authors. 8 references.
Abstract (original language)
The TRISCEND II trial seemingly demonstrates the superiority of transcatheter tricuspid valve replacement over medical treatment for patients with severe functional tricuspid regurgitation.However, closer examination reveals substantial methodological vulnerabilities, including a contentious 2:1 randomization ratio favoring device allocation and lack of blinding.While improvements in quality of life and NYHA functional classification were reported, no significant differences were observed in hard endpoints such as mortality, heart failure hospitalization, right ventricular device implantation or cardiac transplantation.The subjective nature of quality of life assessments using the Kansas City Cardiomyopathy Questionnaire introduces bias.The use of soft endpoints (e.g.quality of life, symptom severity) may artificially inflate the number of events, thereby compromising the trial reliability.Furthermore, the study's demographic composition, predominantly comprising patients with atrial functional tricuspid regurgitation, limits generalizability.Notably, significant device-related complication rates necessitate thorough risk-benefit analysis.In conclusion, the trial fails to provide generalizable results for the majority of patients with severe functional tricuspid regurgitation and is susceptible to bias.Prolonged follow-up is required to assess hard endpoints and mitigate bias induced by soft endpoints.
Cite
APA
García-Villarreal, O. A., Rodríguez-Durán, L. E., & Roldán-Morales, D. (2025). La estrecha ventana del TRISCEND II: un paso adelante, ¿pero qué tan lejos?. Cirugía Cardiaca en México. https://doi.org/10.35366/118937
Vancouver
García-Villarreal OA, Rodríguez-Durán LE, Roldán-Morales D. La estrecha ventana del TRISCEND II: un paso adelante, ¿pero qué tan lejos?. Cirugía Cardiaca en México. 2025. doi:10.35366/118937
BibTeX
@article{GarcaVillarreal2025,
author = {García-Villarreal, Ovidio A and Rodríguez-Durán, Laura E and Roldán-Morales, David},
title = {La estrecha ventana del TRISCEND II: un paso adelante, ¿pero qué tan lejos?},
journal = {Cirugía Cardiaca en México},
year = {2025},
doi = {10.35366/118937}
}
EUVIMED